Home LiteratureArticle Details
PMID: 19776744 Published · ppublish English Historical Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S. Review

The first 30 years of p53: growing ever more complex.

Nature reviews. Cancer ·Vol. 9 ·No. 10 ·2009-00-00 ·Pages 749-58

Levine AJ, Oren M

Abstract

Thirty years ago p53 was discovered as a cellular partner of simian virus 40 large T-antigen, the oncoprotein of this tumour virus. The first decade of p53 research saw the cloning of p53 DNA and the realization that p53 is not an oncogene but a tumour suppressor that is very frequently mutated in human cancer. In the second decade of research, the function of p53 was uncovered: it is a transcription factor induced by stress, which can promote cell cycle arrest, apoptosis and senescence. In the third decade after its discovery new functions of this protein were revealed, including the regulation of metabolic pathways and cytokines that are required for embryo implantation. The fourth decade of research may see new p53-based drugs to treat cancer. What is next is anybody's guess.

MeSH Terms
Animals Genes, p53/genetics History, 20th Century History, 21st Century Humans Neoplasms/genetics,physiopathology Tumor Suppressor Protein p53/genetics,physiology
Chemicals
Tumor Suppressor Protein p53
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Levine Arnold J
Arnold J. Levine is at the Institute for Advanced Study, School of Natural Sciences, Einstein Drive, Princeton, New Jersey 08540, USA. [email protected]
Oren Moshe
References (164)
164 references, click to expand
  1. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome.
    Nature. 1990 Dec 20-27;348(6303):747-9 PMID: 2259385
  2. The retinoblastoma protein and cell cycle control.
    Cell. 1995 May 5;81(3):323-30 PMID: 7736585
  3. Induced p53 expression in lung cancer cell line promotes cell senescence and differentially modifies the cytotoxicity of anti-cancer drugs.
    Oncogene. 1998 Oct 15;17(15):1923-30 PMID: 9788435
  4. Wild-type but not mutant p53 immunopurified proteins bind to sequences adjacent to the SV40 origin of replication.
    Cell. 1991 Jun 14;65(6):1083-91 PMID: 1646078
  5. A transcriptionally active DNA-binding site for human p53 protein complexes.
    Mol Cell Biol. 1992 Jun;12(6):2866-71 PMID: 1588974
  6. SV40 large tumor antigen forms a specific complex with the product of the retinoblastoma susceptibility gene.
    Cell. 1988 Jul 15;54(2):275-83 PMID: 2839300
  7. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours.
    Nature. 1992 Mar 19;356(6366):215-21 PMID: 1552940
  8. Identification of a novel p53 functional domain that is necessary for mediating apoptosis.
    J Biol Chem. 1998 May 22;273(21):13030-6 PMID: 9582339
  9. Isolation and characterization of a human p53 cDNA clone: expression of the human p53 gene.
    EMBO J. 1984 Dec 20;3(13):3257-62 PMID: 6396087
  10. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms.
    Science. 1990 Nov 30;250(4985):1233-8 PMID: 1978757
  11. Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life.
    Mol Cell Biol. 1988 Feb;8(2):531-9 PMID: 2832726
  12. Dynamics of the p53-Mdm2 feedback loop in individual cells.
    Nat Genet. 2004 Feb;36(2):147-50 PMID: 14730303
  13. The guardian's little helper: microRNAs in the p53 tumor suppressor network.
    Cancer Res. 2007 Dec 1;67(23):11099-101 PMID: 18056431
  14. Participation of p53 cellular tumour antigen in transformation of normal embryonic cells.
    Nature. 1984 Dec 13-19;312(5995):646-9 PMID: 6095116
  15. p63: the phantom of the tumor suppressor.
    Cell Cycle. 2007 May 2;6(9):1062-71 PMID: 17426453
  16. The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival.
    Blood. 2008 Oct 15;112(8):3126-9 PMID: 18628487
  17. Restoration of p53 function leads to tumour regression in vivo.
    Nature. 2007 Feb 8;445(7128):661-5 PMID: 17251932
  18. Major deletions in the gene encoding the p53 tumor antigen cause lack of p53 expression in HL-60 cells.
    Proc Natl Acad Sci U S A. 1985 Feb;82(3):790-4 PMID: 2858093
  19. Human p53 cellular tumor antigen: cDNA sequence and expression in COS cells.
    EMBO J. 1985 May;4(5):1251-5 PMID: 4006916
  20. Identification of new polypeptide species (48-55K) immunoprecipitable by antiserum to purified large T antigen and present in SV40-infected and -transformed cells.
    Virology. 1979 Mar;93(2):466-80 PMID: 222051
  21. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound.
    Nat Med. 2002 Mar;8(3):282-8 PMID: 11875500
  22. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a.
    Cell. 1997 Mar 7;88(5):593-602 PMID: 9054499
  23. p53 functions as a cell cycle control protein in osteosarcomas.
    Mol Cell Biol. 1990 Nov;10(11):5772-81 PMID: 2233717
  24. Targeted rescue of a destabilized mutant of p53 by an in silico screened drug.
    Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10360-5 PMID: 18650397
  25. Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells.
    Cell. 1979 May;17(1):43-52 PMID: 222475
  26. Rearrangements of the cellular p53 gene in erythroleukaemic cells transformed by Friend virus.
    Nature. 1985 Apr 18-24;314(6012):633-6 PMID: 3990796
  27. Inactivation of p53 gene expression by an insertion of Moloney murine leukemia virus-like DNA sequences.
    Mol Cell Biol. 1984 Jul;4(7):1402-10 PMID: 6095069
  28. Sequence-specific transcriptional activation is essential for growth suppression by p53.
    Proc Natl Acad Sci U S A. 1994 Mar 15;91(6):1998-2002 PMID: 8134338
  29. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans.
    Cell. 2004 Nov 24;119(5):591-602 PMID: 15550242
  30. p53 enters the microRNA world.
    Cancer Cell. 2007 Nov;12(5):414-8 PMID: 17996645
  31. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia.
    Cell. 1992 Nov 13;71(4):587-97 PMID: 1423616
  32. DNA related to the transforming gene(s) of avian sarcoma viruses is present in normal avian DNA.
    Nature. 1976 Mar 11;260(5547):170-3 PMID: 176594
  33. Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse.
    Proc Natl Acad Sci U S A. 1979 May;76(5):2420-4 PMID: 221923
  34. Participation of p53 protein in the cellular response to DNA damage.
    Cancer Res. 1991 Dec 1;51(23 Pt 1):6304-11 PMID: 1933891
  35. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2.
    Science. 2004 Feb 6;303(5659):844-8 PMID: 14704432
  36. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients.
    Nat Med. 1996 Jul;2(7):811-4 PMID: 8673929
  37. Drosophila p53 binds a damage response element at the reaper locus.
    Cell. 2000 Mar 31;101(1):103-13 PMID: 10778860
  38. Association between an oncogene and an anti-oncogene: the adenovirus E1A proteins bind to the retinoblastoma gene product.
    Nature. 1988 Jul 14;334(6178):124-9 PMID: 2968522
  39. Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells.
    Cancer Cell. 2005 Jun;7(6):547-59 PMID: 15950904
  40. Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line.
    Proc Natl Acad Sci U S A. 1992 May 15;89(10):4495-9 PMID: 1584781
  41. Isolation of a full-length mouse cDNA clone coding for an immunologically distinct p53 molecule.
    Mol Cell Biol. 1985 Jan;5(1):127-32 PMID: 2580227
  42. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53.
    Cell. 1992 Sep 18;70(6):923-35 PMID: 1356076
  43. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors.
    Nat Med. 2004 Dec;10(12):1321-8 PMID: 15558054
  44. UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells.
    Mol Cell Biol. 1984 Sep;4(9):1689-94 PMID: 6092932
  45. Abelson murine leukemia virus-induced tumors elicit antibodies against a host cell protein, P50.
    J Virol. 1980 Nov;36(2):547-55 PMID: 6159484
  46. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53.
    Nature. 1995 Nov 9;378(6553):203-6 PMID: 7477326
  47. Tiny actors, great roles: microRNAs in p53's service.
    Cell Cycle. 2007 Nov 1;6(21):2656-61 PMID: 17957137
  48. Enhanced therapeutic efficacy by simultaneously targeting two genetic defects in tumors.
    Mol Ther. 2009 Jan;17(1):57-64 PMID: 19018252
  49. Purification and partial amino acid sequence analysis of the cellular tumour antigen, p53, from mouse SV40-transformed cells.
    EMBO J. 1983;2(11):1993-9 PMID: 6315411
  50. Reconstitution of p53 expression in a nonproducer Ab-MuLV-transformed cell line by transfection of a functional p53 gene.
    Cell. 1984 Aug;38(1):119-26 PMID: 6088057
  51. Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers.
    Hum Gene Ther. 2005 Sep;16(9):1016-27 PMID: 16149900
  52. p53 has a direct apoptogenic role at the mitochondria.
    Mol Cell. 2003 Mar;11(3):577-90 PMID: 12667443
  53. HdmX stimulates Hdm2-mediated ubiquitination and degradation of p53.
    Proc Natl Acad Sci U S A. 2003 Oct 14;100(21):12009-14 PMID: 14507994
  54. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53.
    Science. 1998 Sep 11;281(5383):1677-9 PMID: 9733515
  55. T antigen is bound to a host protein in SV40-transformed cells.
    Nature. 1979 Mar 15;278(5701):261-3 PMID: 218111
  56. Cooperative DNA binding of p53 with TFIID (TBP): a possible mechanism for transcriptional activation.
    Genes Dev. 1993 Oct;7(10):1837-49 PMID: 8405994
  57. Overproduction of p53 antigen makes established cells highly tumorigenic.
    Nature. 1985 Jul 11-17;316(6024):158-60 PMID: 3892307
  58. Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53.
    Cell. 1990 Aug 24;62(4):671-80 PMID: 2143698
  59. The estrogen receptor alpha pathway induces oncogenic Wip1 phosphatase gene expression.
    Mol Cancer Res. 2009 May;7(5):713-23 PMID: 19435816
  60. Simian virus 40-transformed cells express new species of proteins precipitable by anti-simian virus 40 tumor serum.
    J Virol. 1979 Aug;31(2):472-83 PMID: 225566
  61. Adenovirus E1b-58kd tumor antigen and SV40 large tumor antigen are physically associated with the same 54 kd cellular protein in transformed cells.
    Cell. 1982 Feb;28(2):387-94 PMID: 6277513
  62. Enhanced phosphorylation of p53 by ATM in response to DNA damage.
    Science. 1998 Sep 11;281(5383):1674-7 PMID: 9733514
  63. The regulation of AMPK beta1, TSC2, and PTEN expression by p53: stress, cell and tissue specificity, and the role of these gene products in modulating the IGF-1-AKT-mTOR pathways.
    Cancer Res. 2007 Apr 1;67(7):3043-53 PMID: 17409411
  64. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53.
    Nature. 1995 Nov 9;378(6553):206-8 PMID: 7477327
  65. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation.
    Cell. 1992 Jun 26;69(7):1237-45 PMID: 1535557
  66. Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild-type p53.
    Proc Natl Acad Sci U S A. 1990 Aug;87(16):6166-70 PMID: 2143581
  67. Presence of a potent transcription activating sequence in the p53 protein.
    Science. 1990 Aug 31;249(4972):1046-9 PMID: 2144363
  68. p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours.
    Nature. 2000 Mar 2;404(6773):99-103 PMID: 10716451
  69. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis.
    Mol Cell. 2007 Jun 8;26(5):745-52 PMID: 17540599
  70. The C. elegans homolog of the p53 tumor suppressor is required for DNA damage-induced apoptosis.
    Curr Biol. 2001 Oct 30;11(21):1722-7 PMID: 11696333
  71. The p53 family in differentiation and tumorigenesis.
    Nat Rev Cancer. 2007 Mar;7(3):165-8 PMID: 17332760
  72. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53.
    FEBS Lett. 1997 Dec 22;420(1):25-7 PMID: 9450543
  73. Inactivation of the p53 oncogene by internal deletion or retroviral integration in erythroleukemic cell lines induced by Friend leukemia virus.
    Oncogene. 1988 Aug;3(2):179-85 PMID: 2842714
  74. Blinded by the Light: The Growing Complexity of p53.
    Cell. 2009 May 1;137(3):413-31 PMID: 19410540
  75. Ablation of key oncogenic pathways by RITA-reactivated p53 is required for efficient apoptosis.
    Cancer Cell. 2009 May 5;15(5):441-53 PMID: 19411072
  76. Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest.
    Cell Cycle. 2007 Jul 1;6(13):1586-93 PMID: 17554199
  77. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2.
    Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):8292-7 PMID: 9653180
  78. The jury is in: p73 is a tumor suppressor after all.
    Genes Dev. 2008 Oct 1;22(19):2591-5 PMID: 18832062
  79. A common genetic mechanism in malignant bone marrow diseases.
    N Engl J Med. 2009 May 28;360(22):2355-7 PMID: 19474434
  80. Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation.
    Nature. 1984 Dec 13-19;312(5995):649-51 PMID: 6390217
  81. Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells.
    Proc Natl Acad Sci U S A. 2007 Sep 25;104(39):15472-7 PMID: 17875987
  82. MDM2 inhibitors for cancer therapy.
    Trends Mol Med. 2007 Jan;13(1):23-31 PMID: 17126603
  83. Wip1 phosphatase modulates ATM-dependent signaling pathways.
    Mol Cell. 2006 Sep 1;23(5):757-64 PMID: 16949371
  84. When mutants gain new powers: news from the mutant p53 field.
    Nat Rev Cancer. 2009 Oct;9(10):701-13 PMID: 19693097
  85. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6.
    Nature. 1991 Jul 25;352(6333):345-7 PMID: 1852210
  86. MDMX: a novel p53-binding protein with some functional properties of MDM2.
    EMBO J. 1996 Oct 1;15(19):5349-57 PMID: 8895579
  87. Characterization of different tumor antigens present in cells transformed by simian virus 40.
    Cell. 1979 Oct;18(2):335-46 PMID: 227604
  88. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis.
    Mol Cell. 2007 Jun 8;26(5):731-43 PMID: 17540598
  89. Cancer. p53, guardian of the genome.
    Nature. 1992 Jul 2;358(6381):15-6 PMID: 1614522
  90. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations.
    Science. 1994 Jul 15;265(5170):346-55 PMID: 8023157
  91. Single-nucleotide polymorphisms in the p53 pathway regulate fertility in humans.
    Proc Natl Acad Sci U S A. 2009 Jun 16;106(24):9761-6 PMID: 19470478
  92. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers.
    Cell. 1997 Aug 22;90(4):809-19 PMID: 9288759
  93. Cancer selective adenoviruses.
    Mol Aspects Med. 2007 Feb;28(1):42-58 PMID: 17300834
  94. Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles.
    Cell. 1992 Sep 18;70(6):937-48 PMID: 1525830
  95. p53-mediated activation of miRNA34 candidate tumor-suppressor genes.
    Curr Biol. 2007 Aug 7;17(15):1298-307 PMID: 17656095
  96. Suppression of human colorectal carcinoma cell growth by wild-type p53.
    Science. 1990 Aug 24;249(4971):912-5 PMID: 2144057
  97. The p53-Mdm2 module and the ubiquitin system.
    Semin Cancer Biol. 2003 Feb;13(1):49-58 PMID: 12507556
  98. Caenorhabditis elegans p53: role in apoptosis, meiosis, and stress resistance.
    Science. 2001 Oct 19;294(5542):591-5 PMID: 11557844
  99. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development.
    Nature. 1999 Apr 22;398(6729):714-8 PMID: 10227294
  100. Cytoplasmic functions of the tumour suppressor p53.
    Nature. 2009 Apr 30;458(7242):1127-30 PMID: 19407794
  101. The p53-mdm2 autoregulatory feedback loop: a paradigm for the regulation of growth control by p53?
    Bioessays. 1993 Oct;15(10):689-90 PMID: 7506024
  102. The p53 proto-oncogene can act as a suppressor of transformation.
    Cell. 1989 Jun 30;57(7):1083-93 PMID: 2525423
  103. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53.
    Cell. 1990 Dec 21;63(6):1129-36 PMID: 2175676
  104. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53.
    Nature. 1993 Apr 29;362(6423):857-60 PMID: 8479525
  105. Solution structure of the Hdm2 C2H2C4 RING, a domain critical for ubiquitination of p53.
    J Mol Biol. 2006 Oct 20;363(2):433-50 PMID: 16965791
  106. A single nucleotide polymorphism in the MDM2 gene disrupts the oscillation of p53 and MDM2 levels in cells.
    Cancer Res. 2007 Mar 15;67(6):2757-65 PMID: 17363597
  107. The amino acid sequence of murine p53 determined from a c-DNA clone.
    Virology. 1984 Apr 30;134(2):477-82 PMID: 6400059
  108. Wild-type p53 can down-modulate the activity of various promoters.
    Proc Natl Acad Sci U S A. 1991 Nov 15;88(22):9979-83 PMID: 1946467
  109. Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53.
    Nat Genet. 2001 Sep;29(1):92-5 PMID: 11528400
  110. Heterozygous germline mutations in the p53 homolog p63 are the cause of EEC syndrome.
    Cell. 1999 Oct 15;99(2):143-53 PMID: 10535733
  111. A novel protein with strong homology to the tumor suppressor p53.
    Oncogene. 1997 Sep;15(11):1363-7 PMID: 9315105
  112. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF.
    Cell. 1997 Nov 28;91(5):649-59 PMID: 9393858
  113. Regulation of p53 stability by Mdm2.
    Nature. 1997 May 15;387(6630):299-303 PMID: 9153396
  114. Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry?
    Mol Cancer Res. 2009 Jan;7(1):1-11 PMID: 19147532
  115. Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene.
    Science. 1990 Aug 31;249(4972):1049-51 PMID: 2144364
  116. The transcription factor E2F interacts with the retinoblastoma product and a p107-cyclin A complex in a cell cycle-regulated manner.
    Cell. 1992 Jan 10;68(1):157-66 PMID: 1531040
  117. WAF1, a potential mediator of p53 tumor suppression.
    Cell. 1993 Nov 19;75(4):817-25 PMID: 8242752
  118. ONYX-015: clinical data are encouraging.
    Nat Med. 1998 Dec;4(12):1341-2 PMID: 9846551
  119. The coordinate regulation of the p53 and mTOR pathways in cells.
    Proc Natl Acad Sci U S A. 2005 Jun 7;102(23):8204-9 PMID: 15928081
  120. A review of contusugene ladenovec (Advexin) p53 therapy.
    Curr Opin Mol Ther. 2009 Feb;11(1):54-61 PMID: 19169960
  121. The p53-mdm-2 autoregulatory feedback loop.
    Genes Dev. 1993 Jul;7(7A):1126-32 PMID: 8319905
  122. Clinical trials with oncolytic adenovirus in China.
    Curr Cancer Drug Targets. 2007 Mar;7(2):141-8 PMID: 17346105
  123. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer.
    Nat Med. 1996 Sep;2(9):985-91 PMID: 8782455
  124. p53 polymorphisms: cancer implications.
    Nat Rev Cancer. 2009 Feb;9(2):95-107 PMID: 19165225
  125. p53 isoforms can regulate p53 transcriptional activity.
    Genes Dev. 2005 Sep 15;19(18):2122-37 PMID: 16131611
  126. p53 mutant mice that display early ageing-associated phenotypes.
    Nature. 2002 Jan 3;415(6867):45-53 PMID: 11780111
  127. Meth A fibrosarcoma cells express two transforming mutant p53 species.
    Oncogene. 1988 Sep;3(3):313-21 PMID: 3060794
  128. TAp73 knockout shows genomic instability with infertility and tumor suppressor functions.
    Genes Dev. 2008 Oct 1;22(19):2677-91 PMID: 18805989
  129. Molecular cloning of a cDNA specific for the murine p53 cellular tumor antigen.
    Proc Natl Acad Sci U S A. 1983 Jan;80(1):56-9 PMID: 6296874
  130. Mammalian p53 can function as a transcription factor in yeast.
    Nucleic Acids Res. 1992 Apr 11;20(7):1539-45 PMID: 1579447
  131. p53, a transformation-related cellular-encoded protein, can be used as a biochemical marker for the detection of primary mouse tumor cells.
    Proc Natl Acad Sci U S A. 1983 May;80(9):2613-7 PMID: 6189126
  132. p53 Family isoforms.
    Curr Pharm Biotechnol. 2007 Dec;8(6):332-6 PMID: 18289041
  133. mdm2 expression is induced by wild type p53 activity.
    EMBO J. 1993 Feb;12(2):461-8 PMID: 8440237
  134. A microRNA component of the p53 tumour suppressor network.
    Nature. 2007 Jun 28;447(7148):1130-4 PMID: 17554337
  135. Wild-type p53 can inhibit oncogene-mediated focus formation.
    Proc Natl Acad Sci U S A. 1989 Nov;86(22):8763-7 PMID: 2530586
  136. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents.
    Nat Med. 1997 Jun;3(6):639-45 PMID: 9176490
  137. The antioxidant function of the p53 tumor suppressor.
    Nat Med. 2005 Dec;11(12):1306-13 PMID: 16286925
  138. The Wip1 Phosphatase acts as a gatekeeper in the p53-Mdm2 autoregulatory loop.
    Cancer Cell. 2007 Oct;12(4):342-54 PMID: 17936559
  139. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis.
    Science. 2004 Feb 13;303(5660):1010-4 PMID: 14963330
  140. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities.
    Mol Cell. 1998 Sep;2(3):305-16 PMID: 9774969
  141. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene.
    Cell. 1995 Jan 27;80(2):293-9 PMID: 7834749
  142. Cellular immortalization by a cDNA clone encoding the transformation-associated phosphoprotein p53.
    Nature. 1984 Dec 13-19;312(5995):651-4 PMID: 6095117
  143. p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis.
    Cancer Res. 1990 Dec 1;50(23):7717-22 PMID: 2253215
  144. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas.
    Nature. 2007 Feb 8;445(7128):656-60 PMID: 17251933
  145. Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study.
    Blood. 2008 Oct 15;112(8):3088-98 PMID: 18559976
  146. Molecular cloning and in vitro expression of a cDNA clone for human cellular tumor antigen p53.
    Mol Cell Biol. 1985 Jul;5(7):1601-10 PMID: 3894933
  147. The expanding universe of p53 targets.
    Nat Rev Cancer. 2009 Oct;9(10):724-37 PMID: 19776742
  148. p53 regulates maternal reproduction through LIF.
    Nature. 2007 Nov 29;450(7170):721-4 PMID: 18046411
  149. The mitochondrial p53 pathway.
    Biochim Biophys Acta. 2009 May;1787(5):414-20 PMID: 19007744
  150. Drosophila p53 is a structural and functional homolog of the tumor suppressor p53.
    Cell. 2000 Mar 31;101(1):91-101 PMID: 10778859
  151. Definition of a consensus binding site for p53.
    Nat Genet. 1992 Apr;1(1):45-9 PMID: 1301998
  152. Mdm2 promotes the rapid degradation of p53.
    Nature. 1997 May 15;387(6630):296-9 PMID: 9153395
  153. p53-Repressed miRNAs are involved with E2F in a feed-forward loop promoting proliferation.
    Mol Syst Biol. 2008;4:229 PMID: 19034270
  154. Wild-type p53 activates transcription in vitro.
    Nature. 1992 Jul 2;358(6381):83-6 PMID: 1614538
  155. Analysis of p53-regulated gene expression patterns using oligonucleotide arrays.
    Genes Dev. 2000 Apr 15;14(8):981-93 PMID: 10783169
  156. Identification of p53 as a sequence-specific DNA-binding protein.
    Science. 1991 Jun 21;252(5013):1708-11 PMID: 2047879
  157. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas.
    Nat Rev Cancer. 2006 Dec;6(12):909-23 PMID: 17128209
  158. AMP-activated protein kinase induces a p53-dependent metabolic checkpoint.
    Mol Cell. 2005 Apr 29;18(3):283-93 PMID: 15866171
  159. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas.
    Science. 1989 Apr 14;244(4901):217-21 PMID: 2649981
  160. Sequence-specific DNA binding by p53: identification of target sites and lack of binding to p53 - MDM2 complexes.
    EMBO J. 1993 Jul;12(7):2799-808 PMID: 8334996
  161. Frequent p53 mutations in chemically induced murine fibrosarcoma.
    Oncogene. 1991 Sep;6(9):1593-600 PMID: 1923526
  162. [Isolation of a plasmid clone containing the mRNA sequence for mouse nonviral T-antigen].
    Dokl Akad Nauk SSSR. 1982;267(5):1272-5 PMID: 6295732
  163. The SV40 A gene product is required for the production of a 54,000 MW cellular tumor antigen.
    Virology. 1979 Oct 30;98(2):308-18 PMID: 228475
  164. Two cellular proteins that bind to wild-type but not mutant p53.
    Proc Natl Acad Sci U S A. 1994 Jun 21;91(13):6098-102 PMID: 8016121
Article Info
Journal
Nature reviews. Cancer
Abbr.
Nat Rev Cancer
ISSN
1474-1768
DOI
10.1038/nrc2723
Email
[email protected]
Published
2009-00-00
Pages
749-58
Language
English
Region
England
NLM ID
101124168
PMCID
PMC2771725
Subset
IM
Grants
NCI NIH HHS · P01 CA 87497 · United States
NCI NIH HHS · R37 CA040099 · United States
NCI NIH HHS · R37 CA040099-25 · United States
NCI NIH HHS · P01 CA087497 · United States
NCI NIH HHS · R37 CA40099 · United States
External Links
PubMed source DOI: 10.1038/nrc2723 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2